Details of Disease

General Information of Disease (ID: DISVLL0V)

Disease Name Nasopharyngitis
Synonyms nasopharynx inflammation; inflammation of nasopharynx; chronic nasopharyngitis
Definition An inflammatory process that affects the nasopharynx.
Disease Hierarchy
DISWD40R: Disease
DISZHFZ9: Nasopharyngeal disorder
DIS184KT: Skin inflammation
DISVLL0V: Nasopharyngitis
Disease Identifiers
MONDO ID
MONDO_0001040
MESH ID
D009304
UMLS CUI
C0027441
MedGen ID
6527
SNOMED CT ID
51476001

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 1 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
E2F2 TT5FYX0 Limited Altered Expression [1]
------------------------------------------------------------------------------------
This Disease Is Related to 4 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
PLAC8 OT3SYRUJ Limited Altered Expression [2]
LRRC4 OT7XJ70N moderate Biomarker [3]
AMELX OTIN26MM Strong Genetic Variation [4]
NDUFS4 OTJKUYEE Strong Genetic Variation [5]
------------------------------------------------------------------------------------

References

1 PPAR- Ligand Inhibits Nasopharyngeal Carcinoma Cell Proliferation and Metastasis by Regulating E2F2.PPAR Res. 2019 Aug 1;2019:8679271. doi: 10.1155/2019/8679271. eCollection 2019.
2 Placenta specific 8 gene induces epithelial-mesenchymal transition of nasopharyngeal carcinoma cells via the TGF-/Smad pathway.Exp Cell Res. 2019 Jan 1;374(1):172-180. doi: 10.1016/j.yexcr.2018.11.021. Epub 2018 Nov 26.
3 Expression and clinical significance of LRRC4 in benign and malignant nasopharyngeal diseases.Genet Mol Res. 2015 Dec 9;14(4):16403-9. doi: 10.4238/2015.December.9.9.
4 Safety and efficacy of AMG 714 in patients with type 2 refractory coeliac disease: a phase 2a, randomised, double-blind, placebo-controlled, parallel-group study.Lancet Gastroenterol Hepatol. 2019 Dec;4(12):960-970. doi: 10.1016/S2468-1253(19)30265-1. Epub 2019 Sep 4.
5 Deutetrabenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?.Int J Clin Pract. 2017 Nov;71(11). doi: 10.1111/ijcp.13030. Epub 2017 Oct 12.